SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is seeing intense community speculation ahead of its upcoming earnings report, with traders debating whether a recent surge in bullish call buying reflects a potential breakout or an orchestrated trap. Investors are heavily focused on the company's growth catalysts, including the removal of day-trading restrictions and a substantial share buyback program, while contending with stagnant price action near key support levels.

Applied Digital Corporation

Applied Digital is experiencing a significant surge in investor interest following the announcement of a massive new multi-billion dollar, 15-year lease agreement with a major hyperscaler for its fourth data center campus. The community is actively discussing the stock's strong execution in the AI infrastructure sector, highlighting a significant backlog of contracted revenue and the potential for a mechanical short squeeze as market sentiment shifts heavily toward a bullish outlook.

Micware Co. Ltd. engages in software development services and innovative IT solutions mainly focused on the automotive and mobility sectors. It operates through the following segments: Software Defined Vehicles (SDV), Location-Based Services (LBS), and Others. The SDV segment relates to the development and sale of software systems designed for SDV, including IVI system software and other mobility-enhancing software products, conducted by its Japanese subsidiaries. The LBS segment covers the development and licensing of in-vehicle navigation software systems, and other geographic data-based services for business-to-business customers, mainly serving end users. The Other segment comprises software development services conducted by overseas subsidiaries designed for SDV, and business-to-consumer mobile app services unrelated to in-vehicle navigation. The company was founded by Kenji Narishima in March 2003 and is headquartered in Kobe, Japan.

Micware Co. Ltd. - ADR

Micware Co. Ltd. (MWC) is experiencing extreme volatility and intense community speculation following a major surge triggered by its recent IPO, with investors heavily debating whether the stock is a high-growth opportunity backed by strategic partnerships with major automakers or a classic pump-and-dump scheme. The community is actively tracking technical support levels, analyzing massive volume spikes, and bracing for continued short-squeeze potential while closely monitoring the stock's wide price swings.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently trending as investors debate the sustainability of its rapid valuation growth amidst a broader semiconductor sector pullback and concerns over insider selling. While community sentiment is split between bullish long-term outlooks on its role in AI infrastructure and skepticism regarding its high price-to-earnings ratio, the stock remains a central focus for traders monitoring institutional flows and technical breakouts.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is facing intense volatility as investors weigh a strong Q1 earnings beat and bullish Q2 delivery guidance against broader market concerns and persistent allegations of share price manipulation. While the community is debating whether the stocks current valuation represents a deep-value buying opportunity following consistent quarterly profitability, many retail investors remain frustrated by the stock's stagnant price action relative to its improving fundamentals.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending following the announcement of a 1 billion dollar government grant to establish a domestic quantum chip foundry, sparking intense discussion among investors regarding the company's long-term leadership in quantum computing. The market sentiment is divided, with some community members viewing the funding as a major validation of IBM's strategic pivot to AI and quantum infrastructure, while others remain skeptical about the stock's recent performance and are debating potential entry points for a long-term hold.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit shares are facing intense selling pressure following a double-beat earnings report, as investors focus on a 17% workforce reduction and concerns regarding competitive pricing headwinds. The community is sharply divided between those viewing the decline as a major buying opportunity due to strong fundamentals and share buybacks, and those fearing structural disruption from AI alternatives impacting the company's core tax software business.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following a proposed $100 million equity-backed investment from the U.S. government, sparking intense debate between bulls citing national strategic importance and bears pointing to fundamental concerns regarding low revenue and share dilution. The community remains deeply divided, with active discussion focusing on whether this government endorsement signals a long-term sector mandate or merely a volatile momentum play for speculative traders.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant investor attention driven by high trading volume, recent FedRAMP government re-certification, and community optimism surrounding its QNX software integration in emerging fields like physical AI and robotics. Long-term shareholders are actively debating the company's growth potential and its evolving role in mission-critical edge computing, with many viewing the current price action as a key consolidation phase.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing a surge in community interest driven by a combination of high short interest and a shrinking float fueled by active share repurchases. Investors are actively discussing the potential for a massive short squeeze, comparing the setup to previous market volatility events while emphasizing the company's improving fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Clearmind Medicine Stock Sliding On Wednesday?

Clearmind Medicine Inc. (NYSE: CMND) faces a price correction Wednesday following a massive rally. Read more on the impact of CMND-100 trial results and new executive orders.read more...

US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results

US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric Biosciences, Fitness Champs, Clearmind Medicine surge.read more...

<ul class="summary-bullets"><li>Trump also allocated $50 million in federal funding for related research.</li><li>Clearmind has a patent for a treatment that combines Ibogaine with N-Acylethanolamines.</li><li>Meanwhile, investors are also tracking Silo Pharma, which is currently developing SPC-15, a nasal spray designed to help prevent post-traumatic stress disorder.</li></ul>Shares of Clearmind Medicines (CMND) surged nearly 65% in pre-market trading on Monday, putting the stock on track for its biggest intraday gain since August 2022, after U.S. President Donald Trump signed an executive order to accelerate access to psychedelic-based treatments.Separately, Clearmind Medicine, on Monday, said its drug CMND-100 met the main goal in an early-stage trial for Alcohol Use Disorder. The treatment showed strong safety, with no serious side effects reported, even at higher doses.<h2 class="st-heading-2">$50M PTSD Boost</h2>On Saturday, Trump signed an executive order to accelerate research and access to psychedelic-based therapies, bringing renewed attention to treatments for post-traumatic stress disorder (PTSD). The order directs the U.S. Food and Drug Administration to fast-track the review of drugs such as Ibogaine, while allocating $50 million in federal funding for related research.Ibogaine, derived from a Central and West African shrub, remains a Schedule I substance in the U.S., though interest is rising among veteran groups exploring its therapeutic potential. Officials say the move could pave the way for reclassification if clinical trials prove successful, with decisions potentially coming as early as this summer.<h2 class="st-heading-2">All Eyes On Clearmind’s Ibogaine Combination Therapy</h2>Clearmind has a patent for a treatment that combines Ibogaine with N-Acylethanolamines, a type of fatty acid amide. The patent builds on Clearmind’s collaboration with SciSparc, in which both companies are developing combination therapies pairing psychedelic compounds with molecules such as Palmitoylethanolamide to improve treatment outcomes.Ibogaine has shown promise in clinical studies for treating opioid, cocaine, and other substance use disorders, making it a potential anti-addiction therapy.<a href="https://stocktwits.com/symbol/SILO">SILO stock</a> was down 3% at the time of writing.<h2 class="st-heading-2">Silo’s SPC-15 Development Gets A Boost</h2>Meanwhile, Silo Pharma (SILO) also generated a strong buzz after Trump’s order. The firm is currently developing SPC-15, a nasal spray designed to help prevent post-traumatic stress disorder. The treatment uses a fast nose-to-brain delivery approach. It is being developed under a faster regulatory pathway, the firm added.“Momentum at the national level around psychedelic therapeutics reflects what the science has been signaling for years—there is a critical need for new approaches to treating mental health conditions. We believe Silo is well positioned with SPC-15 and its broader CNS pipeline to potentially benefit from a more favorable regulatory and clinical environment,” said Eric Weisblum, CEO of Silo Pharma.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CMND">CMND</a> on Stocktwits turned ‘extremely bullish, while sentiment for SILO was ‘bullish.’ Message volumes for CMND were ‘extremely high,’ a whopping 535% increase over the past 24 hours, according to Stocktwits data.One user tracking CMND saw the $1.35-$1.37 level as key resistance.<stembedurl>https://stocktwits.com/minimalistreview/message/650748815</stembedurl>Another user highlighted CMND’s “good results,” adding that the stock could climb over $2.<stembedurl>https://stocktwits.com/Maik237/message/650748439</stembedurl>Year-to-date, CMND shares have declined by more than 66%, while SILO stock has climbed by around 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump speaks during a news conference in James S. Brady Press Briefing Room of the White House on April 06, 2026 in Washington, DC. (Photo by Alex Wong/Getty Images)

CMND Stock Set For Biggest Intraday Gains In Over Three Years  — Here’s Why Retail Is Eyeing Further Upside

Psychedelic biotech stocks rallied after a new executive order fast-tracked drug approvals and funding.

Equity

<ul class="summary-bullets"><li>The report, citing sources, said that the federal government is going to look closely at ibogaine’s safety and effectiveness.&nbsp;</li><li>According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans.</li><li>The Trump administration does not intend to reclassify the drug for medical use, instead keeping it a Schedule I drug in the leagues of heroin, the report added.</li></ul>Shares of Psyence Biomedical (PBM) more than doubled on Thursday following media reports that the White House is drafting an executive order that would signal the Trump administration's willingness to further U.S. research into the psychedelic compound called ibogaine.Shares of the company, which is advancing nature-derived psilocybin and ibogaine therapies, traded 141% higher at the time of writing, on track for its best session to date if gains hold.In November, the company said that it has established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs, based in Africa, as it prepares for the clinical development of ibogaine for substance use disorders.<h2 class="st-heading-2">Trump’s Upcoming Executive Order</h2>CBS News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/">reported</a>, citing sources, that the federal government is going to look closely at ibogaine’s safety and effectiveness. However, the Trump administration does not intend to reclassify the drug for medical use, instead keeping it a &nbsp;Schedule I drug in the leagues of heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote that have no acceptable medical use and high potential for abuse.According to the report, President Trump is expected to sign the executive order as soon as this week.Ibogaine is a psychoactive indole alkaloid derived from the West African Tabernanthe iboga shrub. Research into its therapeutic applications for post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and depression is ongoing,According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans, though it is unclear how the government will help facilitate further research.An official told CBS News that medical research into ibogaine is in an early phase, but the administration wants to help determine whether it's "snake oil" or a legitimate treatment.Other companies in the field of psychedelics, including Clearmind Medicine (CMND), AtaiBeckley (ATAI), GH Research (GHRS), and Compass Pathways (CMPS) are also trading higher on the news.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PBM stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘extremely high’ levels.A Stocktwits user noted that PBM stock is subject to “wild swings.”<stembedurl>https://www.stocktwits.com/dippin_stocks/message/650500248</stembedurl>Another user opined that the stock is going to be “highly volatile” but reach double digit.<stembedurl>https://www.stocktwits.com/momoneyinfla/message/650499935</stembedurl><a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has fallen by about 95% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/achv-stock-on-track-for-best-day-in-over-7-years-whats-driving-the-rally/cZJvoz0RIDM">ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Psyence Biomedical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine

CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss? Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment...

Polyrizon Partners With Clearmind To Advance Intranasal MEAI For CNS Disorders

(RTTNews) - Clearmind Medicine (CMND) announced that it has entered into a development agreement with Polyrizon to create a proprietary intranasal formulation of MEAI, a non-hallucinogenic...

Why Did Clearmind Medicine Shares Plunge 29% After Hours?

Clearmind Medicine shares dropped in after-hours trading following the company's announcement of a 1-for-40 reverse stock split.read more...

Penny Stocks To Add to Your Watchlist - November 13th

Leap Therapeutics, Nuvve, Bitfarms, Safe & Green, TNL Mediagene, Strive, and Clearmind Medicine are the seven Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks...

Clearmind Medicine (CMND) Stock Soars Thursday: What's Going On?

Clearmind Medicine Inc (NASDAQ:CMND) shares are trading higher on Thursday. Here's a look at what you need to know.read more...

Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.

Current Price	$2.29
Prev Close	$2.52
Open	$2.50
Dividend Yield	0.00%
50-Day Moving Average	$7.80
Beta	0.39
Avg. Volume	1.37M
PE Ratio	-0.10

52-Week High	$524.00
52-Week Low	$2.20
Market Capitalization	$25.68M
EPS (Annual)	-$30.35
Price to Book	0.46
Revenue Per Employee	N/A

CMND
Clearmind Medicine Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CMND News

CMNDClearmind Medicine Inc